促血小板生成药物在肿瘤治疗相关血小板减少症管理中的应用进展  

Progress in application of platelet stimulating agents in management of cancer therapy-related thrombocytopenia

作　　者：王闫飞 刘巍[1,2] WANG Yanfei;LIU Wei(Day Oncology Unit,Peking University Cancer Hospital&Institute,Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education),Beijing 100142,China;Department of Supportive Care,Peking University Cancer Hospital&Institute,Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education),Beijing 100142,China)

机构地区：[1]北京大学肿瘤医院暨北京市肿瘤防治研究所日间化疗病区,恶性肿瘤发病机制及转化研究教育部重点实验室,北京100142 [2]北京大学肿瘤医院暨北京市肿瘤防治研究所支持治疗科,恶性肿瘤发病机制及转化研究教育部重点实验室,北京100142

出　　处：《肿瘤》2022年第3期203-212,共10页Tumor

基　　金：国家“万人计划”百千万工程领军人才;北京市医院管理局“使命”计划专项(SML20181102)

摘　　要：肿瘤治疗相关血小板减少症(cancer therapy-related thrombocytopenia,CTRT)是抗肿瘤治疗中常见的不良反应。本文对CTRT的现状、促血小板生成药物包括重组人白细胞介素11、重组促血小板生成素和血小板生成素受体激动剂在CTRT领域的研究进展进行综述,并对未来促血小板生成药物治疗CTRT的临床研究方向提出展望,以期为更好地预防和治疗CTRT提供参考依据和建议。Cancer therapy-related thrombocytopenia(CTRT)is a common side effect during anti-cancer therapies.In this paper,the present situation of CTRT,the research progress in platelet-promoting drugs including recombinant human interleukin-11,recombinant thrombopoietin and thrombopoietin receptor agonist in the field of CTRT are reviewed,and the future clinical research direction of the treatment of CTRT with thrombopoietin drugs is prospected,so as to provide references and suggestions for better prevention and treatment of CTRT.

关 键 词：肿瘤治疗相关血小板减少症 促血小板生成药物 白细胞介素11 血小板生成素 血小板生成素受体激动剂 

分 类 号：R558.2[医药卫生—血液循环系统疾病] R730.5[医药卫生—内科学]